Startups
Cystic Fibrosis (CF) is an inherited lung disease with 30,000 US patients with a life expectancy of 37. There is no treatment for 96% of patients and a high unmet clinical need. Novel inhaled lead drug, Procaftor, shows clinically predictive efficacy in a human CF model. CF is an orphan disease with a lean development model. Our experienced CF drug development team are asking for a $8m to fund a 3 year IND to end of Phase 2a with several investor exits. We anticipate peak US sales of $1.2bn.
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 10, 2013 | For new Rhode Island firm, peptides hold hope for disease-altering cystic fibrosis treatments | Procaftor, Calista’s lead candidate, is designed to restore function to the CFTR transporter in the lungs and prevent the buildup of thick mucus. President and CEO Andrew Mallon said that preclinical studies have suggested clinical efficacy... |
| For new Rhode Island firm, peptides hold hope for disease-altering cystic fibrosis treatments | It’s been nearly two-and-a-half decades since the gene associated with the inherited disease cystic fibrosis was discovered, paving the way for disease-modifying drugs. In that time, only one such drug has been approved in the U.S. and Euro... | |
| UNC spinout looking to one-up Kalydeco with one-size-fits-all cystic fibrosis therapy | Cystic fibrosis has become the poster child for precision medicine – most new therapies are carefully tailored to a CF patient’s genetic makeup. University of North Carolina spinout Spyryx Biosciences is proposing a one-size-fits-all approa... |
Reviews 0
FAQ about Calista Therapeutics
What has the press written about Calista Therapeutics?
Parsers VC has collected 4 articles mentioning Calista Therapeutics, among them “For new Rhode Island firm, peptides hold hope for disease-altering cystic fibrosis treatments” (Jun 10, 2013) and “For new Rhode Island firm, peptides hold hope for disease-altering cystic fibrosis treatments”.
Is Calista Therapeutics still active?
Yes, Calista Therapeutics is active; its latest activity on Parsers VC dates from Feb 13, 2015.